Table 1.
Characteristics of SARS-COV-2-infected patients suffering from chronic kidney disease
| Study cohort: Chronic kidney disease |
|
|---|---|
| Included cases | 426 |
| Age—no. (%) | |
| 15–65 | 86 (20.2) |
| 66–75 | 83 (19.5) |
| 76–85 | 169 (39.7) |
| > 85 | 88 (20.7) |
| Sex—no. (%) | |
| Female | 175 (41.1) |
| Male | 251 (58.9) |
| Country of residence—no. (%) | |
| Germany | 419 (98.4) |
| Turkey | 3 (0.7) |
| Austria | 3 (0.7) |
| Spain | 1 (0.2) |
| BMI—no. (%) | |
| < 18.5 kg/m2 | 6 (2.1) |
| 18.5–24.9 kg/m2 | 119 (40.8) |
| 25–29.9 kg/m2 | 99 (33.9) |
| 30–34.9 kg/m2 | 46 (15.7) |
| ≥ 35 kg/m2 | 22 (7.5) |
| Comorbidities—no. (%) | |
| Hypertension | 339 (80.7) |
| Chronic heart failure | 132 (33.1) |
| Atrial fibrillation | 135 (32.5) |
| Coronary heart disease | 133 (33.5) |
| Cerebrovascular disease | 76 (18.6) |
| Diabetes mellitus | 171 (41.1) |
| COPD | 53 (12.7) |
| Oncological diseasea | 85 (20.7) |
| GFR categories (KDIGO)—no. (%) | |
| G1 (GFR ≥ 90 ml/min) | 17 (5.4) |
| G2 (GFR 60–89 ml/min) | 42 (13.4) |
| G3 (GFR 30–59 ml/min) | 149 (47.6) |
| G4 (GFR 15–29 ml/min) | 41 (13.1) |
| G5 (GFR < 15 ml/min) | 64 (20.5) |
| Causes of CKD—no. (%) | |
| Vascular-hypertensive disease | 70 (50.4) |
| Secondary glomerular disease | 30 (21.6) |
| Primary glomerular disease | 13 (9.3) |
| Idiopathic kidney disease | 10 (7.2) |
| Obstructive nephropathy | 7 (5.0) |
| Tubulointerstitial disease | 4 (2.9) |
| Polycystic kidney disease | 4 (2.9) |
| Congenital disease | 1 (0.7) |
| Kidney transplantation—no. (%) | |
| Kidney transplantation | 25 (6.1) |
| Dialysis—no. (%) | |
| On dialysis | 75 (18.2) |
| Hemodialysis | 62 (96.9) |
| Peritoneal dialysis | 2 (3.1) |
| Smoking status—no. (%) | |
| Active smoker | 27 (13.2) |
| Former smoker | 41 (20.0) |
| Non smoker | 137 (66.8) |
| Medication—no. (%) | |
| ACE inhibitors or ARBsb | 222 (55.2) |
| Immunosuppressive medicationc | 74 (19.7) |
Continuous parameters were collected in categories. All variables are expressed as numbers (no.) and percentages (%) referred to the numbers excluding missing data. Missing rates and frequency distribution are displayed in Suppl. Table 2 for variables with missing rate > 5%
BMI body mass index, COPD chronic obstructive pulmonary disease, GFR glomerular filtration rate, CKD chronic kidney disease, KDIGO Kidney Disease: Improving Global Outcomes, ACE inhibitors angiotensin-converting enzyme inhibitor, ARBs angiotensin II receptor blocker
aLeukemia, lymphoma or solid tumor
bAt first positive SARS-CoV-2 detection
cWithin the last 3 months